f Targeting PPARs in the Brain: From Old Knowledge to Emerging Therapeutic Roles

References

1. CooremanM.P. VonghiaL. FrancqueS.M. MASLD/MASH and type 2 diabetes: Two sides of the same coin? From single PPAR to pan-PPAR agonists.Diabetes Res. Clin. Pract.202421211168810.1016/j.diabres.2024.111688 38697298
   [Google Scholar]
2. De FilippisB. GraneseA. AmmazzalorsoA. Peroxisome proliferator-activated receptor agonists and antagonists: An updated patent review (2020-2023).Expert Opin. Ther. Pat.2024341-2839810.1080/13543776.2024.2332661 38501260
   [Google Scholar]
3. FantacuzziM. AmorosoR. AmmazzalorsoA. PPAR ligands induce antiviral effects targeting perturbed lipid metabolism during SARS-CoV-2, HCV, and HCMV infection.Biology202211111410.3390/biology11010114 35053112
   [Google Scholar]
4. AmmazzalorsoA. BrunoI. FlorioR. Sulfonimide and amide derivatives as novel PPARα antagonists: Synthesis, antiproliferative activity, and docking studies.ACS Med. Chem. Lett.202011562463210.1021/acsmedchemlett.9b00666 32435362
   [Google Scholar]
5. WardenA. TruittJ. MerrimanM. Localization of PPAR isotypes in the adult mouse and human brain.Sci. Rep.2016612761810.1038/srep27618 27283430
   [Google Scholar]
6. Sáez-OrellanaF. LeroyT. RibeiroF. Regulation of PPARα by APP in Alzheimer disease affects the pharmacological modulation of synaptic activity.JCI Insight2021616e15009910.1172/jci.insight.150099 34228639
   [Google Scholar]
7. RibeiroR.T. MarcuzzoM.B. CarvalhoA.V.S. Protective effects of the PPAR agonist bezafibrate against disruption of redox and energy homeostasis, neuronal death, astroglial reactivity, and neuroinflammation induced in vivo by D-2-hydroxyglutaric acid in rat brain.Eur. J. Pharmacol.202598717718610.1016/j.ejphar.2024.177186 39647572
   [Google Scholar]
8. ZolezziJ.M. SantosM.J. Bastías-CandiaS. PintoC. GodoyJ.A. InestrosaN.C. PPARs in the central nervous system: roles in neurodegeneration and neuroinflammation.Biol. Rev. Camb. Philos. Soc.20179242046206910.1111/brv.12320 28220655
   [Google Scholar]
9. NisbettK.E. PinnaG. Emerging therapeutic role of PPAR-α in cognition and emotions.Front. Pharmacol.2018999810.3389/fphar.2018.00998 30356872
   [Google Scholar]
10. StrosznajderA.K. WójtowiczS. JeżynaM.J. SunG.Y. StrosznajderJ.B. Recent insights on the role of PPAR-β/δ in neuroinflammation and neurodegeneration, and its potential target for therapy.Neuromolecular Med.2021231869810.1007/s12017‑020‑08629‑9 33210212
    [Google Scholar]
11. ZubarevaO.E. KharisovaA.R. RoginskayaA.I. PPARβ/δ agonist GW0742 modulates microglial and astroglial gene expression in a rat model of temporal lobe epilepsy.Int. J. Mol. Sci.202425181001510.3390/ijms251810015 39337503
    [Google Scholar]
12. PengJ. WangK. XiangW. LiY. HaoY. GuanY. Rosiglitazone polarizes microglia and protects against pilocarpine‐induced status epilepticus.CNS Neurosci. Ther.201925121363137210.1111/cns.13265 31729170
    [Google Scholar]
13. ViñaJ. EscuderoJ. BaqueroM. Genistein effect on cognition in prodromal Alzheimer’s disease patients. The GENIAL clinical trial.Alzheimers Res. Ther.202214116410.1186/s13195‑022‑01097‑2 36329553
    [Google Scholar]